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Super-resistant Plasmodium falciparum threatens the 
effectiveness of sulfadoxine–pyrimethamine in intermittent 
preventive treatment for malaria during pregnancy. It is char-
acterized	by	the	A581G	Pfdhps mutation on a background 
of the double-mutant Pfdhps and the triple-mutant Pfdhfr. 
Using	samples	collected	during	2004–2008,	we	investigat-
ed	the	evolutionary	origin	of	the	A581G	mutation	by	charac-
terizing	microsatellite	diversity	flanking	Pfdhps triple-mutant 
(437G+540E+581G)	alleles	from	3	locations	in	eastern	Af-
rica	and	comparing	it	with	double-mutant	(437G+540E)	al-
leles from the same area. In Ethiopia, both alleles derived 
from 1 lineage that was distinct from those in Uganda and 
Tanzania. Uganda and Tanzania triple mutants derived from 
the previously characterized southeastern Africa double-
mutant	lineage.	The	A581G	mutation	has	occurred	multiple	
times on local Pfdhps double-mutant backgrounds; how-
ever, a novel microsatellite allele incorporated into the Tan-
zania	lineage	since	2004	illustrates	the	local	expansion	of	
emergent triple-mutant lineages.
Controlling and reducing malaria requires a combina-tion of vector control measures and administration 
of antimalarial drugs as prophylaxis or treatment (1). The 
widespread use of antimalarial drugs has resulted in the 
emergence of resistant Plasmodium falciparum, recurrently 
exposing persons in malaria-endemic regions to an unac-
ceptably high risk for treatment failures (2).
Highly chloroquine-resistant parasites spread from 
Asia in the 1960s and led to devastating rates of malaria-
related death in Africa starting in the late 1980s, gradu-
ally forcing affected countries to replace chloroquine with 
sulfadoxine–pyrimethamine (SP) (3–5). The effectiveness 
of SP did not last long. In fact, retrospective analysis indi-
cated that pyrimethamine-resistant parasites were present 
in sub-Saharan Africa before SP was implemented as first-
line treatment, probably because pyrimethamine as mono-
therapy had been used in Asia during the 1960’s and 1970’s 
(6–8). Resistance to sulfadoxine also soon emerged (9), 
and the combination of pyrimethamine- and sulfadoxine- 
resistant parasites led to severe and widespread SP treat-
ment failure (10–12). As a consequence, affected coun-
tries were once again forced to change their drug policies 
(13) and have now adopted artemisinin-based combina-
tion therapies as first-line treatment for uncomplicated 
malaria. Yet, SP is still recommended for use as intermit-
tent preventive treatment in pregnant women (SP-IPTp) 
and infants (SP-IPTi) (14,15). Also, seasonal malaria 
chemoprevention applies SP in combination with amodia-
quine (16). Use of SP for prevention in many countries of 
sub-Saharan Africa, where clinical failure after SP treat-
ment has been reported, underscores the need for effective 
surveillance of its protective efficacy and for monitoring 
of the development and spread of SP resistance in P. fal-
ciparum populations.
The molecular basis of SP resistance is a combination 
of single-nucleotide polymorphisms (SNPs) in 2 distinct 
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genes coding for the target enzymes of SP. The enzymes 
dihydrofolate reductase (DHFR) and dihydropteroate syn-
thetase (DHPS) are targeted by pyrimethamine and sulfa-
doxine, respectively (17). High-level pyrimethamine re-
sistance is generally encoded by 3 mutations in the Pfdhfr 
gene, coding for substitutions: N51I, C59R, and S108N 
(18); the molecular basis of sulfadoxine resistance is 
caused by substitutions S/A436F, A437G, K540E, A581G, 
and A613S/T in a variety of combinations in DHPS (19).
The most prevalent genotype in eastern Africa is a 
combination of the Pfdhfr triple mutant (51I, 59R, and 
108N, denoted as IRN) combined with the Pfdhps double 
mutant (S436, 437G, 540E, A581, and A613, denoted as 
SGEAA). Together, this combination of SNPs is referred 
to as the “quintuple” mutant Pfdhfr/Pfdhps genotype and 
is associated with high risk for SP treatment failure (17) 
and results in limited protective value of SP-IPTi (20). Ac-
cordingly, the World Health Organization (WHO) recom-
mends that SP-IPTi should be implemented only when the 
prevalence of the K540E mutation (and thus the quintuple 
mutant) is <50% (14).
More recently, an alanine to glycine mutation at co-
don position 581 in Pfdhps has emerged that, in combina-
tion with the Pfdhfr triple-mutant allele IRN, was shown 
to confer higher level resistance (21). This combination, 
referred to as the “sextuple Pfdhfr/Pfdhps mutant geno-
type” or the “super-resistant genotype” (22), is associated 
with reduced SP-IPTp efficacy by 1) a reduction in the 
protection period of SP-IPTp from 4 weeks to 2 weeks 
(23); 2) increased parasitemia attributed to competitive 
facilitation (23); 3) increased risk for severe malaria in 
the offspring (24); and 4) low birthweight in newborns 
from mothers undergoing SP-IPTp in Tanzania (25). Con-
sequently, WHO recommendations concerning the use 
of SP-IPTp base the threshold on 2 mutations: SP-IPTp 
should be discontinued if the prevalence of the K540E 
mutation is >95% and the A581G mutation is >10% (20). 
No threshold in the prevalence of molecular markers of 
resistance has been set with regard to seasonal malaria 
chemoprevention (15,16).
Maps collating all published data from molecular sur-
veillance of Pfdhfr and Pfdhps mutations (22) indicate 3 
main foci of super-resistant parasites: 1 in northern Tanzania 
(26); a second in southwestern Uganda, Rwanda, and bor-
dering areas of Democratic Republic of Congo (27–29); 
and a third in western Kenya (30). Prevalence of A581G 
also is high in Ethiopia and northern Sudan, where it again 
occurs as the Pfdhps triple-mutant allele SGEGA but in 
combination with a Pfdhfr double-mutant allele 51I-108N.
Assessments of microsatellite variation linked to 
Pfdhps have shown that limited microsatellite diversity 
flanking the SGEAA double mutants compared with the 
SAKAA wild types. Two SGEAA lineages were discov-
ered in eastern Africa: 1 prevailing in northeastern Africa 
(Ethiopia and Sudan) and the other throughout south-
eastern Africa. Both lineages derived from independent 
ancestry (10). Here we apply the same approach, using 
the same microsatellite loci, to determine the ancestry 
and possible relationship between the double SGEAA and 
triple SGEGA alleles in Ethiopia, Uganda, and Tanzania. 
By focusing on microsatellite variation linked to Pfdhps, 
we can explore whether the emergence of the SP-IPT-
threatening SGEGA triple mutants in Ethiopia, Uganda, 
and Tanzania derive from local SGEAA alleles or are be-
ing imported.
Materials and Methods
Study Sites
Samples for the study were collected during 2004–
2008. Study sites were in Uganda (2 sites), Tanzania 
(3 sites), and Ethiopia (1 site) (Table).
Sample Collection
Bufundi and Rikungiri, Uganda
Uganda implemented SP-IPTp in 2000 and has not 
implemented SP-IPTi or seasonal malaria chemopreven-
tion. Finger-prick blood-spot samples were obtained from 
symptomatic patients of all ages after P. falciparum in-
fection was confirmed by a Paracheck rapid test (Orchid 
Biomedical Systems, Chennai, India) during May–Decem-
ber 2005 at reference health facilities in Bufundi (Kabale 
District) (38 samples) and Kebisoni (Rukungiri District) 
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Table. Study sites and number of samples genotyped for super-resistant Plasmodium falciparum, eastern Africa* 
Study site. 
SGEAA  SGEGA Total haplotype 
diversity No. samples Haplotype	diversity  No. samples Haplotype	diversity 
Ethiopia,	Humera,	Tigray 35 4  41 1 4 
Uganda       
 Bufundi,	Kabale 24 5  14 3 7 
 Kebisoni,	Rukungiri 27 5  14 3 7 
Tanzania       
 Hale,	Tanga 21 6  15 3 8 
 Korogwe,	Tanga 64 21  19 3 22 
 Magoda, Tanga 7 3  15 6 6 
*By country, district, village. Samples from Ethiopia are from	2004;	samples	from	Uganda	are	from	2005;	and	samples	from	Tanzania	are	from	2004	
(Korogwe	only),	2006	(Korogwe	and	Hale),	2007	(Korogwe	only)	and	2008	(Magoda	only). 
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(41 samples). Blood spots were air dried on Whatman no. 
3 filter paper (VWR–Bie & Berntsen, Herlev, Denmark), 
sealed in plastic bags with a desiccant, and stored at room 
temperature for molecular genotyping (27). The Uganda 
National Council for Science and Technology (UNSCT HS 
35) and the ethics committee of the London School of Hy-
giene and Tropical Medicine (London, UK) gave scientific 
and ethical permission. Consent was obtained from all per-
sons or their guardians before sample collection.
Hale, Korogwe, and Magoda, Tanzania
Tanzania implemented SP-IPTp in 2001 and has not 
implemented SP-IPTi or seasonal malaria chemoprevention. 
Samples were obtained from 3 different settings in Tanga re-
gion. From Hale (36 samples), finger-prick blood-spot sam-
ples were taken from symptomatic children 6–59 months of 
age who attended Hale Health Centre during July–August 
2006 as previously described (21). The study protocol was 
approved by the Ethics Review Committees of the National 
Institute for Medical Research, Tanzania, and the London 
School of Hygiene and Tropical Medicine and was regis-
tered as a clinical trial with the National Institutes of Health 
(http://www.clinicaltrials.gov, identifier NCT00361114). 
From Korogwe (83 samples), finger-prick or venous blood 
samples were obtained on filter paper from children and ado-
lescents <20 years of age from Mkokola and Kwamasimba 
villages. Samples were collected in March 2004, May 2006, 
and May 2007, as described (26). The Medical Research Co-
ordinating Committee of the National Institute for Medical 
Research and Ministry of Health, Tanzania, granted ethical 
clearance for the study. All participants or their parents or 
guardians provided informed consent. Samples from Ma-
goda villages (22 samples) were collected from children <5 
years of age in June 2008 as part of a cross-sectional assess-
ment of malaria prevalence (31).
Humera, Ethiopia
Ethiopia has adopted neither of the WHO recommen-
dations regarding use of SP as prophylaxis. Samples were 
collected from patients of all ages who attended Kahsay 
Abera Hospital in Humera during January–April 2004 and 
who had symptomatic uncomplicated malaria (10). The pa-
tients were enrolled in an in vivo efficacy trial, comparing 
artemether–lumefantrine therapy with SP therapy, which 
was conducted by staff of Kahsay Abera Hospital and the 
Mekele Regional Health Bureau. Finger-prick blood-spot 
samples were taken from patients before treatment after 
they gave written informed consent to participate in the 
study, and genetic analysis was conducted in support of the 
drug efficacy evaluation. The Ethical Clearance Commit-
tee of the Tigray Health Research Council and the external 
Ethics Review Board used by Médecins sans Frontières 
gave ethical permissions for the study.
Genotyping
Sample collection at the different study sites was not 
standardized because the samples derived from independent 
studies. However, all samples consisted of finger-prick blood 
spots stored on filter paper, and parasite DNA was extracted 
by using the Chelex method (32).
Point mutations in samples from Hale, Tanzania, were 
determined by direct sequencing (21). Sequencing was per-
formed by using the ABI-3730 automatic sequencer (Ap-
plied Biosystems, Foster City, CA, USA), and samples were 
analyzed with Applied Biosystems BigDye V. 3.1 (Applied 
Biosystems).
For all other samples, the polymorphic region of Pfdhps 
was PCR-amplified before sequence-specific oligonucle-
otide probing (SSOP) for mutations at codons 436, 437, 540, 
581, and 613 by using primers and PCR conditions described 
elsewhere (33). SSOP-genotyping of samples from Uganda 
and Ethiopia was conducted according to an SSOP–dot-blot 
method (10); genotyping of samples from Korogwe and 
Magoda in Tanzania was conducted according to an SSOP-
ELISA method (33).
Only samples containing the Pfdhps SGEAA or SGE-
GA alleles were included for further analysis; other alleles, 
such as wild-type or single-mutant alleles, were excluded. In 
general, only a single sequence was detected at every codon, 
but if the sequence analysis detected a mixture, these sam-
ples were handled as mixed infections. Mixed infections, in 
turn, were further analyzed only if 1 allele was substantially 
in the majority (i.e., a 2:1 signal ratio between the dominant 
genotype and the minor genotype) and a majority SNP could 
be confidently determined at all codon positions (33).
Microsatellite Analysis
Analysis was performed on 3 Pfdhps-linked microsatel-
lites located 0.8 kb (marker [m.] 0.8), 4.3 kb (m. 4.3), and 7.7 
kb (m. 7.7) downstream of the coding position 437 of Pfdhps, 
located on chromosome 8 (34). Microsatellites were ampli-
fied by seminested PCR as described previously (34), and 
products were run with GeneScan-500 LIZ Size Standards 
(Applied Biosystems) in an ABI 3730 DNA analyzer (Ap-
plied Biosystems) and analyzed by using Genemapper soft-
ware (Applied Biosystems). If >1 microsatellite allele was de-
tected in any given sample, the peak height ratio was used to 
determine the majority allele for that locus. If the major allele 
did not have a peak height of at least double the height of the 
minor allele, the sample was excluded from further analysis.
Microsatellite haplotypes were constructed by combin-
ing alleles detected in each of the 3 microsatellite loci. Sam-
ples with missing data were not included.
Results
A total of 300 samples with either Pfdhps double-
mutant (SGEAA) or triple-mutant (SGEGA) alleles were 
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subjected to microsatellite analysis, and 277 (92.3%) of 
these gave conclusive results. Microsatellite haplotypes as-
sociated with the Pfdhps double- and triple-mutant alleles 
are listed in full (online Technical Appendix Table, http://
wwwnc.cdc.gov/EID/article/20/8/13-1897-Techapp1.pdf), 
where the haplotypes are ranked hierarchically according 
to allele size, first at the 0.8-kb locus, then at 4.3-kb locus, 
and finally at the 7.7-kb locus, and each unique haplotype 
was assigned a number.
Diversity of Microsatellite Composition among  
SGEAA Samples
SGEAA alleles from Ethiopia were associated with 
4 different microsatellite haplotypes (Figure, panel A; 
Table). Haplotype 4 (notation 121–114–98, refers to frag-
ment size 121 bp at the 0.8-kb locus, 114 bp at the 4.3-kb 
locus, and 98 bp at the 7.7-kb locus) predominated and was 
found in 30 (85.7%) of the 35 SGEAA alleles sampled. Of 
the remaining 3 microsatellite haplotypes, haplotypes 7 and 
21 were each found twice; 11 was found once. Haplotype 
11 (131–104–107) was most common in the samples from 
Uganda and Tanzania. No samples from Tanzania or Ugan-
da were Ethiopia haplotype 4. The Uganda SGEAA alleles 
were associated with 8 different microsatellite haplotypes 
(Figure, panel A; online Technical Appendix Table, 5 hap-
lotypes found at each site); the most common haplotype, 
haplotype 11 (131–104–107), was found in 82.4%, (42/51) 
of samples. The 92 SGEAA samples collected from 3 study 
sites in Tanzania exhibited 24 different microsatellite hap-
lotypes (Figure, panel A; online Technical Appendix Ta-
ble). Korogwe exhibited the greatest diversity by having 21 
haplotypes among 64 SGEAA sample. As in Uganda, most 
of the Tanzania SGEAA alleles were associated with hap-
lotype 11 (53 [57.6%]). Among the remaining 39 samples 
were 23 alternative but related haplotypes.
Diversity of Microsatellite Composition among  
SGEGA Samples
Of 41 SGEGA samples from Ethiopia, only 1 micro-
satellite haplotype was present: haplotype 4 (121–114–98) 
(Figure, panel B; online Technical Appendix Table). The 
28 SGEGA samples from Uganda were associated with 
3 microsatellite haplotypes; all 3 combinations were rep-
resented in the 2 sites (Figure, panel B; online Appendix 
Table). Of these SGEGA samples, 24 (85.7%) were hap-
lotype 11 (131–104–107). The 2 less common haplotypes, 
haplotypes 18 (131–104–125) and 14 (131–104–113), are 
evidently related to haplotype 11, differing by 1 allele at 
the 7.7-kb locus. Of 49 SGEGA samples collected from 
Tanzania, we found 7 microsatellite haplotypes (Figure, 
panel B; online Technical Appendix Table). This finding 
indicates less diversity than was associated with SGEAA 
alleles: Hale (3 haplotypes), Korogwe (3 haplotypes), and 
Magoda (6 haplotypes). Of the Tanzania SGEGA samples, 
18 (36.7%) were haplotype 11, the same haplotype com-
mon among Tanzania and Uganda SGEAA samples and 
among Uganda SGEGA samples. Of the remaining 28 
SGEGA samples from Tanzania, 24 (49.0% of total Tanza-
nia SGEGA samples) were haplotype 18 (131–104–125), 
a haplotype found only twice in association with SGEAA 
samples from Tanzania. This haplotype was found twice 
among Uganda SGEGA samples and never among Uganda 
SGEAA samples.
Discussion
Although SP is no longer recommended as first-line 
treatment for P. falciparum infection, it is widely recom-
mended for prevention and possibly still available over the 
counter for self-treatment. Presumably, therefore, SP has 
continued to exert selective pressure on already resistant 
parasites, which might explain the continuing emergence 
of the triple-mutant Pfdhps allele (SGEGA), which is cur-
rently being described for certain regions of eastern Africa. 
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Figure.	Proportion	of	microsatellite	haplotypes	linked	to	SGEAA	and	
SGEGA, eastern Africa. Microsatellite haplotypes associated with 
the Pfdhps double-mutant allele SGEAA (A) and Pfdhps triple-mutant 
allele	 SGEGA	 (B)	 in	 Ethiopia,	 Tanzania,	 and	 Uganda.	 Haplotype	
numbering (x-axis) refers to a unique combination of microsatellite 
allele	sizes	at	the	3	loci	linked	to	dhps	(specific	microsatellite	allele	
combinations	are	listed	in	the	online	Technical	Appendix	Table	[http://
wwwnc.cdc.gov/EID/article/20/8/13-1897-	Techapp1.pdf].	Proportion	
(y-axis) is the number of alleles associated with each microsatellite 
haplotype expressed as a proportion of the total number of alleles 
sampled in each country for which the associated microsatellite 
haplotype could be determined.
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An increased prevalence of the A581G mutation has been 
well documented in eastern Africa in recent years; it in-
creased from 12% in 2003 to 56% in 2007 at study sites 
in Korogwe, Tanzania (26). In Kabale and Rukungiri, 
Uganda, samples from 2005 showed a high prevalence of 
the A581G mutation at 45% and 46%, respectively (27); 
studies during 2005–2006 in Rukara and Mahesha, Rwan-
da, observed prevalences of 60% and 29%, respectively 
(28). A study in 2010 in Huye District, Southern Province, 
Rwanda, reported a prevalence of 63% (35). In eastern 
Sudan, a study found an increase in the prevalence of the 
A581G mutation from 14% in 2003 to 34% in 2012 (36). In 
Kenya, Kisumu, a study showed an increase in the A581G 
mutation from 0% in 1999–2000 to 85% in 2003–2005 
(30). More recently, in Nyanza Province, western Kenya, 
the prevalence of the A581G increased from 0% to 5.3% 
from 2008–2009 (37).
In this study, we investigated the origins of triple-mu-
tant Pfdhps alleles by analyzing the microsatellite diversity 
flanking Pfdhps. We sampled both SGEAA double mutants 
and SGEGA triple mutants in 3 populations at the key mo-
ment: when the SGEGA triple mutant had emerged but had 
not yet replaced the SGEAA double mutant. At this time, 
double- and triple-mutant alleles were present in similar 
numbers in the areas, but SP-sensitive alleles were very rare.
In Ethiopia, both SGEAA and SGEGA alleles were 
associated with haplotype 4 (121–114–98), indicating 
a shared ancestry that has evolved independently from 
SGEAA and SGEGA alleles from Uganda and Tanzania. 
The SGEAA in these 2 countries were associated with lin-
eage 11 (131–104–107), the same microsatellite haplotype 
previously shown to be associated with the double-mutant 
alleles throughout Tanzania, Kenya, Uganda, Mozam-
bique, and Zambia (10).
In Ethiopia and Uganda, we found evidence that the most 
prevalent SGEAA haplotype locally had given rise to SGE-
GA haplotypes in the same area; the most common SGEAA 
haplotype was also the most common SGEGA haplotype in 
both countries (haplotypes 4 and 11, respectively). However, 
in Tanzania, the microsatellite haplotype most commonly as-
sociated with SGEGA (haplotype 18 [131–104–125], 25/49 
samples) was not identical to that most commonly associated 
with SGEAA (haplotype 11 [131–104–107]), because only 2 
SGEAA samples were haplotype 18. This finding leads us to 
speculate that the A581G mutation has emerged on at least 2 
occasions in Tanzania.
We found that the microsatellite diversity associated 
with both SGEAA and SGEGA haplotypes in Ethiopia 
samples was less than in the SGEAA and SGEGA samples 
from sites in Uganda and Tanzania. The high level of ho-
mozygosity among microsatellite haplotypes in Ethiopia 
might be due to a high degree of selective pressure, which 
in turn might be assisted by population bottlenecks brought 
about by a narrow malaria transmission season and limited 
exchange of parasites, with neighboring regions resulting 
from limited migration. The Ethiopia samples originate 
from the Tigray District near the Eritrean border. Despite 
some migration of refugees from Eritrea to Ethiopia, a sub-
stantial spread to and from the Tigray District in Ethiopia 
during the years before sample collection is doubtful be-
cause of the continued presence of forces at the border dur-
ing the cease fire succeeding the Eritrean–Ethiopian war 
initiated in 2000. Double- and triple-mutant alleles from 
northeastern and eastern Sudan also are associated with 
haplotype 4 (121–114–98) (10) and represent greater di-
versity than what we present from Ethiopia, which supports 
the view that the parasite populations in these 2 countries 
are linked (10,38).
Tanzania is a capital of trade and emigration for sub-
Saharan Africa. The Tanzam highway (running from Tan-
zania through Zambia) is one of the most trafficked roads 
on the African continent, and higher diversity and sharing 
of common microsatellite haplotypes among the Ugandan 
and Tanzanian populations were therefore expected. A 
recent publication about the correlation between human 
population movement and malaria movement in Uganda, 
Tanzania, and Kenya (39) illustrates that the major human 
population movement and malaria movement in Tanzania 
originates from central Dodoma and directs northward and 
westward. In this regard, an early selection of a haplotype 
in the Tanga region (northeast) compared with other areas 
of Tanzania, can be speculated to be plausible because of 
the larger levels of parasite migration to northern and west-
ern parts of the country, diluting to some extent the newly 
selected haplotypes in these areas.
In conclusion, we provide evidence that the A581G 
mutation can arise on various SGEAA ancestral back-
grounds, of which we have shown 3 different cases (haplo-
types 4, 11, and 18), from areas previously known to repre-
sent 2 distinct parasite lineages. Our microsatellite analysis 
is consistent with reports that the SGEGA triple-mutant 
alleles are undergoing rapid expansion, and we found evi-
dence of spread of the Tanzania SGEGA haplotype (hap-
lotype 18) as far as southwestern Uganda, which illustrates 
the potential for dispersal of super-resistant P. falciparum 
malaria throughout the region. Given the rate of increase 
and the ability of double-mutant allele lineages to acquire 
the super resistance–conferring A581G mutation indepen-
dently, it is vital for the continuing effectiveness of prophy-
laxis with SP that more comprehensive surveillance for the 
A581G mutation be used to track emerging super-resistant 
malaria in Africa.
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